

## Recarbrio® (imipenem/cilastatin/relebactam) – New indication

- On June 4, 2020, the FDA announced the approval of Merck's Recarbrio (imipenem/cilastatin/relebactam), for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by the following susceptible gram-negative microorganisms: Acinetobacter calcoaceticus-baumannii complex, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Serratia marcescens.
- Recarbrio is also approved for the treatment of complicated urinary tract infections, including pyelonephritis, and complicated intra-abdominal infections.
- HABP and VABP are a type of pneumonia that occurs in hospitalized patients and can cause symptoms such as fever, chills, cough, chest pain and increased oxygen requirements.
- The approval of Recarbrio for the new indication was based on a randomized, double-blind study in 535 hospitalized adults with HABP/VABP. Patients were randomized to Recarbrio or piperacillin/tazobactam (eg, <a href="Zosyn">Zosyn</a> for 7 to 14 days of therapy. The modified intent-to-treat (mITT) population included 531 randomized patients who received at least one dose of trial treatment and did not have only gram-positive cocci on Gram stain of the baseline lower respiratory tract specimen. Efficacy outcomes included incidence of all-cause mortality through day 28 and clinical response at the early follow-up (EFU) visit (7 to 14 days after the end of therapy) in the mITT population.
  - All-cause mortality was 15.9% in patients who received Recarbrio and 21.3% in patients who received piperacillin/tazobactam through day 28 of the study (treatment difference: -5.3; 95% CI: -11.9, 1.2).
  - Clinical response at the EFU visit was achieved in 61.0% of patients receiving Recarbrio and 55.8% of patients receiving piperacillin/tazobactam (treatment difference: 5.0; 95% CI: -3.2, 13.2).
- The most common adverse reactions (≥ 5%) with Recarbrio use for the treatment of HABP/VABP were increased alanine aminotransferase, increased aspartate aminotransferase, anemia, diarrhea, hypokalemia, and hyponatremia.
- The recommended dose of Recarbrio for all its indications is 1.25 grams (imipenem 500 mg/cilastatin 500 mg/relebactam 250 mg) administered by intravenous infusion over 30 minutes every 6 hours in patients 18 years of age and older with creatinine clearance of 90 mL/min or greater.
  - The severity and location of infection, as well as clinical response should guide the duration of therapy. The recommended duration of treatment with Recarbrio is 4 days to 14 days.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.